Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
FBFibroBiologics, Inc. logo

FibroBiologics, Inc. (FBLG)

NASDAQ Capital Market · Currency in USD
$0.95 ▼ -0.07 (-6.86%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.96 ▲ +0.01 (+1.05%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$1.02
Open
$1.00
Day's Range
$0.95 – $1.02
52 Week Range
$0.62 – $9.60
Volume
111,902
Avg. Volume
196,508
Market Cap
$6.33M
Beta (5Y Monthly)
1.22
PE Ratio (TTM)
--
EPS (TTM)
-$4.81
Earnings Date
Oct 30, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$180.00

Profile: FibroBiologics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
15
CEO
Peter O'Heeron

FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers.

Earnings

Next report: Fri, Oct 30, 2026
EPS estimate -$0.63
DateEst.Actual
Jul 31, 2026-$0.93-$0.66Beat
Apr 30, 2026-$1.26-$1.33Miss
Feb 24, 2026-$1.44-$0.98Beat
Oct 31, 2025-$2.00-$2.60Miss
Jul 31, 2025-$0.11-$2.40Miss
May 14, 2025-$2.00-$2.80Miss

Analyst view

Consensus price target
$180.00 ▲ +18,847.4%
Range $180.00 – $180.00
Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on FBLG and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.